within Pharmacolibrary.Drugs.ATC.N;

model N06DA04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00025666666666666665,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.175,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.020833333333333332,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.188,
    k12             = 15.2,
    k21             = 15.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Galantamine is a reversible, competitive acetylcholinesterase inhibitor used primarily for the treatment of mild to moderate Alzheimer's disease to improve cognition and slow cognitive decline. It is approved and widely used today in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers following single oral administration.</p><h4>References</h4><ol><li><p>El-Ganainy, SO, et al., &amp; Hanafy, AS (2021). Galantamine nanoparticles outperform oral galantamine in an Alzheimer&#x27;s rat model: pharmacokinetics and pharmacodynamics. <i>Nanomedicine (London, England)</i> 16(15) 1281–1296. DOI:<a href=\"https://doi.org/10.2217/nnm-2021-0051\">10.2217/nnm-2021-0051</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34013783/\">https://pubmed.ncbi.nlm.nih.gov/34013783</a></p></li><li><p>Agrawal, M, et al., &amp; Alexander, A (2018). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 281 139–177. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2018.05.011\">10.1016/j.jconrel.2018.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29772289/\">https://pubmed.ncbi.nlm.nih.gov/29772289</a></p></li><li><p>Bakker, C, et al., &amp; Groeneveld, GJ (2020). Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine. <i>Alzheimer&#x27;s &amp; dementia (New York, N. Y.)</i> 6(1) e12093–None. DOI:<a href=\"https://doi.org/10.1002/trc2.12093\">10.1002/trc2.12093</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33083515/\">https://pubmed.ncbi.nlm.nih.gov/33083515</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DA04;
